Scheme of treatment schedule is shown in Figure 3A. Intratumoral administration of OAV, OAV-DEC, or intravenous infusion of CAIX-CAR-T monotherapy had moderate antitumor activity in the models tested, with tumor growth inhibition rates of 28.1%, 40.7%, and 54.4%, respectively (Figures 3B and 3C). This evidence concerns the gene CA9 and neoplasm.